hypogonadotropic hypogonadism

(redirected from secondary hypogonadism)

hypogonadism

 [hi″po-go´nad-izm]
decreased functional activity of the gonads, with retardation of growth, sexual development, and secondary sex characters. The American Association of Clinical Endocrinologists has published “Clinical Practice Guidelines for the Evaluation and Treatment of Hypogonadism in Adult Male Patients.” These are available online at their web site: http://www.aace.com.
hypergonadotropic hypogonadism that associated with secretion of high levels of gonadotropins, as in Klinefelter's syndrome. Called also hypergonadotropic eunuchoidism.
hypogonadotropic hypogonadism that due to lack of gonads or of gonadotropin secretion. Called also hypogonadotropic eunuchoidism.

hy·po·gon·a·do·trop·ic hy·po·go·nad·ism

[MIM*146110]
defective gonadal development or function, or both, resulting from inadequate secretion of pituitary gonadotropins.

hypogonadotropic hypogonadism

Hypogonadotropic eunuchoidism, Kallman syndrome A rare condition with a highly variable hereditary pattern, characterized by secondary hypogonadism–↓ gonadotropin-releasing hormone due to hypothalamic or pituitary dysfunction with testicular failure, and anosmia–due to hypoplasia or aplasia of the olfactory bulbs and tracts, 2º to a defect in the migration of olfactory neurons, and neurons producing GRH–gonadotropin-releasing hormone; ↓ FSH and LH impairs sperm and androgen production Clinical Delayed puberty, micropenis, eunuchoid features, cryptorchidism, midline defects–eg, cleft lip and palate, unilateral renal agenesis, horseshoe kidney, nerve deafness and hearing loss, color blindness, skeletal abnormalities; synkinesia, spatial attention defects, spastic paraplegia, cerebellar dysfunction, horizontal nystagmus, pes cavus, mental retardation Management Androgens to induce anatomic maturation; gonadotropins or LH-releasing factor for spermatogenesis. See Kalig-1.

hypogonadotropic hypogonadism

A usually congenital condition in which there is a severe deficiency of the gonadotropin-releasing hormone (GnRH) of the pituitary gland. As a rulethe penis remains infantile and the testes do not descend into the scrotum (cryptorchidism). No sexual development occurs at puberty. In rare cases the condition may develop in men who had previous normal secondary sexual development and a normal puberty. This leads to loss of libido, impotence and infertility. In these cases, treatment with gonadotropin-releasing hormone can reverse all the features of the disorder.
References in periodicals archive ?
The most relevant forms of secondary hypogonadism are prolactinemia, which has several etiologies and thus a variable prevalence, and Kallmann syndrome, which affects 1 in 10 000.
There appear to be two separate tracks to primary hypogonadism marked by testicular dysfunction: secondary hypogonadism and compensated hypogonadism.
Fispemifene's product profile offers an exciting next-generation treatment option for men suffering from urological conditions such as secondary hypogonadism, in an existing multi-billion dollar market.
If luteinizing hormone and follicle-stimulating hormone levels are low (or inappropriately normal), secondary hypogonadism is diagnosed and hypothalamic/pituitary pathologies should be considered (11, 12) depending on the patient's presentation.
The drug is being developed for the treatment of secondary hypogonadism, or a defect of the gonads that results in the underproduction of testosterone.
Fispemifene is a new, selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men.
Before transplantation, 3 had primary hypogonadism, and 2 had secondary hypogonadism.
R])(NasdaqCM:RPRX) today reported it has submitted to the FDA a reanalysis of the previously completed 200 subject trial ZA-003 of Androxal([R]) in the treatment of secondary hypogonadism as noted by Repros in the Company's press release of November 9, 2010.
The Company planned on seeking guidance on its planned New Drug Application (NDA) for Androxal for the treatment of secondary hypogonadism with preservation of testicular function.
Patients with secondary hypogonadism (hypothalamic-pituitary) have low T and normal LH and FSH levels.
The small study involved men with secondary hypogonadism who were receiving testosterone replacement treatment.
Androgen replacement should be considered for men on high-dose ICSs who are found to have secondary hypogonadism with low testosterone levels.

Full browser ?